Hypersensitivity Reactions to Cancer Chemotherapy: Practical Recommendations of ARADyAL for Diagnosis and Desensitization
No Thumbnail Available
Identifiers
Date
2021-01-01
Authors
Vega, A.
Jimenez-Rodriguez, T-W
Barranco, R.
Bartra, J.
Dieguez, M. C.
Dona, I
Fernandez-Rivas, M.
Gandolfo-Cano, M.
Gastaminza-Lasarte, G.
Gonzalez-Mancebo, E.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Esmon publicidad s a, dept allergy & clin immunol, clin univ navarra
Metrics
Export
Abstract
Rapid drug desensitization has enabled first-line therapies in patients with drug hypersensitivity reactions to chemotherapeutic drugs including monoclonal antibodies. Desensitization is a safe and highly effective procedure, not only for IgE-mediated reactions, but also for those mediated by non-IgE mechanisms. The likelihood of breakthrough reactions during desensitization is low, and most are mild; in fact, moderate-to-severe reactions are infrequent. In this document, 16 allergy departments belonging to the Spanish research network ARADyAL present a review of the available scientific evidence and provide general guidelines for the diagnosis and management of drug hypersensitivity reactions to chemotherapeutic drugs and monoclonal antibodies. Emphasis is placed on the desensitization procedure.
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
Drug allergy, Drug hypersensitivity, Desensitization, Chemotherapy, Drug challenge, Monoclonal antibodies, Successful oral desensitization, Hereditary alpha-tryptasemia, Rapid drug desensitization, Basophil activation test, Stevens-johnson-syndrome, Monoclonal-antibodies, Ige desensitization, Skin-test, Carboplatin hypersensitivity, General-considerations